{"id":"NCT04345471","sponsor":"Mochida Pharmaceutical Company, Ltd.","briefTitle":"A Study of MD-120 in Patients With Depression","officialTitle":"A Placebo-controlled Study of MD-120 in Patients With Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-18","primaryCompletion":"2022-07-21","completion":"2022-09-14","firstPosted":"2020-04-14","resultsPosted":"2024-02-29","lastUpdate":"2024-02-29"},"enrollment":615,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Desvenlafaxine 100 mg","otherNames":[]},{"type":"DRUG","name":"Desvenlafaxine 50 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MD-120 100 mg","type":"EXPERIMENTAL"},{"label":"MD-120 50 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.","primaryOutcome":{"measure":"Changes in Total MADRS Score From the Baseline to Week 8 Visit During the Treatment Period","timeFrame":"8 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-10.4,"sd":0.7},{"arm":"MD-120 50 mg","deltaMin":-11.1,"sd":0.7},{"arm":"MD-120 100 mg","deltaMin":-11.9,"sd":0.7}],"pValues":[{"comp":"OG000 vs OG001","p":"0.509"},{"comp":"OG000 vs OG002","p":"0.131"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":204},"commonTop":["Nausea","Somnolence","Dizziness","Nasopharyngitis","Pyrexia"]}}